Filipe Pereira Sarmento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Filipe Pereira Sarmento has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Resende Gondim Jasmineiro Pitanga
Departamento de Microbiología, Parasitología e Inmunología, Universidad de Buenos Aires, Argentina
4 shared publications - Murilo Marmori Cruccioli
Departamento de Medicina, Universidade Evangélica de Goiás, Anápolis, Brazil
4 shared publications - Pedro Fraiman
Division of General Neurology and Ataxia Unit, Department of Neurology and Neurosurgery Universidade Federal de São Paulo São Paulo Brazil
4 shared publications - Pedro Henrique Teixeira Carneiro
Departamento de Medicina, Universidade de Santo Amaro, São Paulo, Brazil
4 shared publications - Letícia Torres da Silva
Departamento de Medicina, Universidade de São Paulo, Brazil
3 shared publications - Michael Scott Okun
University of Florida
3 shared publications
Latest Publications
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (2)
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (2)
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (1) , e200567
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
Neurocysticercosis is the most common parasitic infection of the CNS and remains a significant, yet often neglected, public health issue in endemic regions. High-quality evidence suggests that albendazole monotherapy leads to superior clinical outcomes compared with placebo or praziquantel. However, there is still insufficient evidence regarding the efficacy and safety of combined albendazole-praziquantel therapy. This systematic review and meta-analysis aims to compare combined antiparasitic therapy with albendazole and praziquantel with albendazole monotherapy, evaluating whether dual therapy offers superior therapeutic benefits in the management of neurocysticercosis while maintaining an acceptable safety profile. We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published until April 2024 that compared combined albendazole-praziquantel therapy with albendazole monotherapy for the treatment of neurocysticercosis. Statistical analysis was performed using Review Manager 5.4.1, with odds ratios (ORs) and 95% confidence intervals (CIs) reported. A random-effects model was applied to all end points. The risk of bias was assessed for each study, and the certainty of evidence was evaluated using the GRADE approach. Five RCTs were included, comprising a total of 320 patients, 49% of whom received combined therapy. Complete cyst resolution was significantly more frequent in patients treated with combined albendazole-praziquantel therapy compared with albendazole monotherapy (OR = 3.06; 95% CI [1.81-5.19]; p = 0.0001; I 2 = 5%; high-certainty evidence). In a subgroup analysis restricted to patients with 1-2 cysts (248 patients), no statistically significant difference in complete cyst resolution was observed (OR = 1.98; 95% CI [0.92-4.27]; p = 0.08; I 2 = 34%; very-low-certainty evidence). There was no significant difference in seizure recurrence between treatment strategies (OR = 1.28, 95% CI [0.56-2.91], p = 0.55, I 2 = 0%; moderate-certainty evidence). Similarly, the incidence of adverse effects did not differ significantly between groups (OR = 1.40, 95% CI [0.72-2.72], p = 0.30, I 2 = 0%; moderate-certainty evidence). This systematic review and meta-analysis demonstrated a threefold increase in complete cyst resolution among patients receiving combined therapy, suggesting its superiority over albendazole monotherapy for the management of neurocysticercosis. In addition, no significant differences were observed between treatment strategies regarding seizure or adverse events.
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (1) , e200567
Albendazole-Praziquantel Dual Therapy Compared With Albendazole Monotherapy in Neurocysticercosis
Neurocysticercosis is the most common parasitic infection of the CNS and remains a significant, yet often neglected, public health issue in endemic regions. High-quality evidence suggests that albendazole monotherapy leads to superior clinical outcomes compared with placebo or praziquantel. However, there is still insufficient evidence regarding the efficacy and safety of combined albendazole-praziquantel therapy. This systematic review and meta-analysis aims to compare combined antiparasitic therapy with albendazole and praziquantel with albendazole monotherapy, evaluating whether dual therapy offers superior therapeutic benefits in the management of neurocysticercosis while maintaining an acceptable safety profile. We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published until April 2024 that compared combined albendazole-praziquantel therapy with albendazole monotherapy for the treatment of neurocysticercosis. Statistical analysis was performed using Review Manager 5.4.1, with odds ratios (ORs) and 95% confidence intervals (CIs) reported. A random-effects model was applied to all end points. The risk of bias was assessed for each study, and the certainty of evidence was evaluated using the GRADE approach. Five RCTs were included, comprising a total of 320 patients, 49% of whom received combined therapy. Complete cyst resolution was significantly more frequent in patients treated with combined albendazole-praziquantel therapy compared with albendazole monotherapy (OR = 3.06; 95% CI [1.81-5.19]; p = 0.0001; I 2 = 5%; high-certainty evidence). In a subgroup analysis restricted to patients with 1-2 cysts (248 patients), no statistically significant difference in complete cyst resolution was observed (OR = 1.98; 95% CI [0.92-4.27]; p = 0.08; I 2 = 34%; very-low-certainty evidence). There was no significant difference in seizure recurrence between treatment strategies (OR = 1.28, 95% CI [0.56-2.91], p = 0.55, I 2 = 0%; moderate-certainty evidence). Similarly, the incidence of adverse effects did not differ significantly between groups (OR = 1.40, 95% CI [0.72-2.72], p = 0.30, I 2 = 0%; moderate-certainty evidence). This systematic review and meta-analysis demonstrated a threefold increase in complete cyst resolution among patients receiving combined therapy, suggesting its superiority over albendazole monotherapy for the management of neurocysticercosis. In addition, no significant differences were observed between treatment strategies regarding seizure or adverse events.
- 25 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (5) , 1-7
Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.
- 25 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (5) , 1-7
Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.
- 27 August 2025
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Haloperidol Versus Atypical Antipsychotics for Delirium in Hospitalized and ICU Patients: A Systematic Review and Meta-analysis
Background: While there is still debate over the benefit of antipsychotics in delirium management, surveys indicate their frequent use in clinical practice. Previous systematic reviews and meta-analyses have focused on assessing the effectiveness of antipsychotics versus placebo in delirium management. However, despite increasing access to atypical antipsychotics in hospital settings, robust analyses of studies comparing the effectiveness of haloperidol and atypical antipsychotics are lacking. Objectives: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effectiveness and safety of haloperidol versus atypical antipsychotics in the management of delirium patients. Methods: We conducted a systematic search of Medline, Scopus, and Cochrane for RCTs comparing atypical antipsychotics with haloperidol in delirium patients. Odds ratio (OR) was used to analyze dichotomous variables. Continuous outcomes were compared using mean difference (MD) and standardized mean difference (SMD). The random effects model was applied to all endpoints. Results: Eleven RCTs (n=1450 patients) met the eligibility criteria. Delirium severity (SMD, −0.03; [95% CI, −0.20 to 0.15]; P = 0.78) and overall mortality (OR, 1.26; [95% CI, 0.88-1.80]; P = 0.20) did not differ significantly between groups. However, patients treated with haloperidol had significantly higher odds of experiencing extrapyramidal symptoms compared with those treated with atypical antipsychotics (OR, 2.72; [95% CI, 1.26-5.87]; P = 0.01). Conclusions: While there were no significant differences in the effectiveness between treatments, patients treated with haloperidol had nearly a 3-fold increase in the incidence of extrapyramidal symptoms, indicating a potential advantage of atypical antipsychotics in minimizing adverse effects.
- 27 August 2025
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Haloperidol Versus Atypical Antipsychotics for Delirium in Hospitalized and ICU Patients: A Systematic Review and Meta-analysis
Background: While there is still debate over the benefit of antipsychotics in delirium management, surveys indicate their frequent use in clinical practice. Previous systematic reviews and meta-analyses have focused on assessing the effectiveness of antipsychotics versus placebo in delirium management. However, despite increasing access to atypical antipsychotics in hospital settings, robust analyses of studies comparing the effectiveness of haloperidol and atypical antipsychotics are lacking. Objectives: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effectiveness and safety of haloperidol versus atypical antipsychotics in the management of delirium patients. Methods: We conducted a systematic search of Medline, Scopus, and Cochrane for RCTs comparing atypical antipsychotics with haloperidol in delirium patients. Odds ratio (OR) was used to analyze dichotomous variables. Continuous outcomes were compared using mean difference (MD) and standardized mean difference (SMD). The random effects model was applied to all endpoints. Results: Eleven RCTs (n=1450 patients) met the eligibility criteria. Delirium severity (SMD, −0.03; [95% CI, −0.20 to 0.15]; P = 0.78) and overall mortality (OR, 1.26; [95% CI, 0.88-1.80]; P = 0.20) did not differ significantly between groups. However, patients treated with haloperidol had significantly higher odds of experiencing extrapyramidal symptoms compared with those treated with atypical antipsychotics (OR, 2.72; [95% CI, 1.26-5.87]; P = 0.01). Conclusions: While there were no significant differences in the effectiveness between treatments, patients treated with haloperidol had nearly a 3-fold increase in the incidence of extrapyramidal symptoms, indicating a potential advantage of atypical antipsychotics in minimizing adverse effects.
- Open Access
- 8 December 2024
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 14 (8) , 1614-1622
Motor outcomes in unilateral, bilateral rapid, and bilateral delayed staging deep brain stimulation for Parkinson’s disease
Background: Deep brain stimulation (DBS) is effective in managing motor symptoms in select cases of Parkinson's disease (PD). Nonetheless, the ideal timing for surgery and the comparative outcomes of unilateral versus bilateral DBS procedures remain under-researched areas. Objective: We aimed to compare the impact of unilateral and bilateral DBS on the motor manifestations of PD using standardized Unified Parkinson's Disease Rating Scale Part-III (UPDRS-III). Methods: We conducted a retrospective analysis of PD patients who underwent multidisciplinary DBS screening which made a formal recommendation for surgical approach. We compared unilateral, bilateral “rapid” (less than 2 months apart), and bilateral “staged” (5–11 months apart) implantation approaches. The study included 90 patients, 48 patients, and 42 patients from the 3 groups, respectively. The primary outcome was the percentage improvement in baseline off UPDRS-III scores compared to medication-off/DBS-on conditions at 3–6 months and 10–14 months post-surgery. Mann-Whitney U tests were used to compare scores within groups and across follow-up periods. The Kruskal-Wallis test assessed differences among groups. Furthermore, multiple regression analyses were performed to adjust for confounding variables. Results: UPDRS-III scores improved significantly from baseline at both follow-up intervals regardless of the type of DBS staging approach. The Kruskal-Wallis test revealed no significant differences in UPDRS-III percentage improvement among groups at 3–6 months (p = 0.125) and 10–14 months (p = 0.298) post-DBS. Conclusions: Our study revealed that in a single experienced DBS center which employed multidisciplinary screening, assignment to unilateral and bilateral DBS, both rapid and staged, targeting the STN or GPi, effectively improved motor symptoms for up to 14 months.
- 8 December 2024
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 14 (8) , 1614-1622
Open AccessMotor outcomes in unilateral, bilateral rapid, and bilateral delayed staging deep brain stimulation for Parkinson’s disease
Background: Deep brain stimulation (DBS) is effective in managing motor symptoms in select cases of Parkinson's disease (PD). Nonetheless, the ideal timing for surgery and the comparative outcomes of unilateral versus bilateral DBS procedures remain under-researched areas. Objective: We aimed to compare the impact of unilateral and bilateral DBS on the motor manifestations of PD using standardized Unified Parkinson's Disease Rating Scale Part-III (UPDRS-III). Methods: We conducted a retrospective analysis of PD patients who underwent multidisciplinary DBS screening which made a formal recommendation for surgical approach. We compared unilateral, bilateral “rapid” (less than 2 months apart), and bilateral “staged” (5–11 months apart) implantation approaches. The study included 90 patients, 48 patients, and 42 patients from the 3 groups, respectively. The primary outcome was the percentage improvement in baseline off UPDRS-III scores compared to medication-off/DBS-on conditions at 3–6 months and 10–14 months post-surgery. Mann-Whitney U tests were used to compare scores within groups and across follow-up periods. The Kruskal-Wallis test assessed differences among groups. Furthermore, multiple regression analyses were performed to adjust for confounding variables. Results: UPDRS-III scores improved significantly from baseline at both follow-up intervals regardless of the type of DBS staging approach. The Kruskal-Wallis test revealed no significant differences in UPDRS-III percentage improvement among groups at 3–6 months (p = 0.125) and 10–14 months (p = 0.298) post-DBS. Conclusions: Our study revealed that in a single experienced DBS center which employed multidisciplinary screening, assignment to unilateral and bilateral DBS, both rapid and staged, targeting the STN or GPi, effectively improved motor symptoms for up to 14 months.
- Open Access
- 23 November 2024
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 11, 100288
Exploring the layers of fatigue in Parkinson’s Disease: A comprehensive analysis of its prevalence and contributing factors
- 23 November 2024
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 11, 100288
Open AccessExploring the layers of fatigue in Parkinson’s Disease: A comprehensive analysis of its prevalence and contributing factors
- Open Access
- 4 September 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (12) , 001-003
Complex movement disorders in early onset hypoparathyroidism
A 23-year-old female patient with long-standing untreated idiopathic hypoparathyroidism presented with complex involuntary movements. Physical examination revealed generalized dystonia, painful spasms, and stereotypies ([Video 1]). Brain magnetic resonance imaging ([Figure 1]) and brain CT ([Figure 2]) revealed extensive bilateral calcification. Video 1. Complex movement disorders in early onset hypoparathyroidism. Hypoparathyroidism can present with a variety of neurological symptoms ([Figure 3]), including, though less commonly, movement disorders such as chorea, parkinsonism, dystonia, choreoathetosis, and paroxysmal dyskinesia.[1] [2] Notably, stereotypic-like movements were only previously described by Galvez-Jimenez et al.[1] Central nervous system calcifications are present in up to 74% of patients with hypoparathyroidism.[3] Despite its prevalence, there is no clear relationship between the location and extent of the calcifications and the clinical phenotype.[3] FPS: conceptualization, data curation, project administration, supervision, writing – original draft, writing – review & editing; JVGT, SMG: writing – original draft, writing – review & editing; LFF: data curation, writing – review & editing; OGPB: supervision; JLP: conceptualization, data curation, project administration, supervision, writing – review & editing. Received: 24 May 2024 Accepted: 29 June 2024 Article published online: 04 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 4 September 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (12) , 001-003
Open AccessComplex movement disorders in early onset hypoparathyroidism
A 23-year-old female patient with long-standing untreated idiopathic hypoparathyroidism presented with complex involuntary movements. Physical examination revealed generalized dystonia, painful spasms, and stereotypies ([Video 1]). Brain magnetic resonance imaging ([Figure 1]) and brain CT ([Figure 2]) revealed extensive bilateral calcification. Video 1. Complex movement disorders in early onset hypoparathyroidism. Hypoparathyroidism can present with a variety of neurological symptoms ([Figure 3]), including, though less commonly, movement disorders such as chorea, parkinsonism, dystonia, choreoathetosis, and paroxysmal dyskinesia.[1] [2] Notably, stereotypic-like movements were only previously described by Galvez-Jimenez et al.[1] Central nervous system calcifications are present in up to 74% of patients with hypoparathyroidism.[3] Despite its prevalence, there is no clear relationship between the location and extent of the calcifications and the clinical phenotype.[3] FPS: conceptualization, data curation, project administration, supervision, writing – original draft, writing – review & editing; JVGT, SMG: writing – original draft, writing – review & editing; LFF: data curation, writing – review & editing; OGPB: supervision; JLP: conceptualization, data curation, project administration, supervision, writing – review & editing. Received: 24 May 2024 Accepted: 29 June 2024 Article published online: 04 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- Open Access
- 30 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-9
Chronic intracranial recordings in the globus pallidus reveal circadian rhythms in Parkinson’s disease
Circadian rhythms have been shown in the subthalamic nucleus (STN) in Parkinson’s disease (PD), but only a few studies have focused on the globus pallidus internus (GPi). This retrospective study investigates GPi circadian rhythms in a large cohort of subjects with PD (130 recordings from 93 subjects) with GPi activity chronically recorded in their home environment. We found a significant change in GPi activity between daytime and nighttime in most subjects (82.4%), with a reduction in GPi activity at nighttime in 56.2% of recordings and an increase in activity in 26.2%. GPi activity in higher frequency bands ( > 20 Hz) was more likely to decrease at night and in patients taking extended-release levodopa medication. Our results suggest that circadian fluctuations in the GPi vary across individuals and that increased power at night might be due to the reemergence of pathological neural activity. These findings should be considered to ensure successful implementation of adaptive neurostimulation paradigms in the real-world.
- 30 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-9
Open AccessChronic intracranial recordings in the globus pallidus reveal circadian rhythms in Parkinson’s disease
Circadian rhythms have been shown in the subthalamic nucleus (STN) in Parkinson’s disease (PD), but only a few studies have focused on the globus pallidus internus (GPi). This retrospective study investigates GPi circadian rhythms in a large cohort of subjects with PD (130 recordings from 93 subjects) with GPi activity chronically recorded in their home environment. We found a significant change in GPi activity between daytime and nighttime in most subjects (82.4%), with a reduction in GPi activity at nighttime in 56.2% of recordings and an increase in activity in 26.2%. GPi activity in higher frequency bands ( > 20 Hz) was more likely to decrease at night and in patients taking extended-release levodopa medication. Our results suggest that circadian fluctuations in the GPi vary across individuals and that increased power at night might be due to the reemergence of pathological neural activity. These findings should be considered to ensure successful implementation of adaptive neurostimulation paradigms in the real-world.
- Open Access
- 7 February 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (02) , 001-002
Segmental areas of denervation in post-polio syndrome
A one-year-old male disclosed motor developmental delay, appendicular hypotonia, hyporeflexia, and weakness in the left lower limb. He started walking only at three years old. After this time, his symptoms were stable. At 31 years old, the patient started slight asymmetric and slowly progressive paraparesis and myalgia. He was referred with a suspicion of spinal muscular atrophy. Electromyography disclosed bilateral chronic lumbosacral denervation and mild acute denervation involving the right lower limb. Neuroimaging studies (brain and spinal MRI) and genetic testing (MLPA test for quantification of SMN1 and SMN2 copy numbers and hereditary neuropathy, non-5q, and other motor neuron disease panels) were normal. Muscle MRI disclosed asymmetric neurogenic muscle “islands” alternating areas with and without fatty replacement ([Figure 1]),[1] suggestive of Post-Poliomyelitis Syndrome (PPS).[2] [3] Muscle MRI is useful to distinguish PPS from other motor neuron diseases.[1] [2] [3] VLB: conceptualization, data curation, formal analysis, writing – original draft preparation and supervision; HLCM, PHAF, FPS: conceptualization, formal analysis, writing – original draft preparation; IBF: conceptualization, data curation and writing – original draft preparation; PLS: BMLB, MATC, WBVRP: Conceptualization, data curation, formal analysis, writing – review & editing and supervision; PVSS, ASBO: Conceptualization, data curation and writing – review & editing. Received: 15 October 2023 Accepted: 03 December 2023 Article published online: 23 February 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 7 February 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (02) , 001-002
Open AccessSegmental areas of denervation in post-polio syndrome
A one-year-old male disclosed motor developmental delay, appendicular hypotonia, hyporeflexia, and weakness in the left lower limb. He started walking only at three years old. After this time, his symptoms were stable. At 31 years old, the patient started slight asymmetric and slowly progressive paraparesis and myalgia. He was referred with a suspicion of spinal muscular atrophy. Electromyography disclosed bilateral chronic lumbosacral denervation and mild acute denervation involving the right lower limb. Neuroimaging studies (brain and spinal MRI) and genetic testing (MLPA test for quantification of SMN1 and SMN2 copy numbers and hereditary neuropathy, non-5q, and other motor neuron disease panels) were normal. Muscle MRI disclosed asymmetric neurogenic muscle “islands” alternating areas with and without fatty replacement ([Figure 1]),[1] suggestive of Post-Poliomyelitis Syndrome (PPS).[2] [3] Muscle MRI is useful to distinguish PPS from other motor neuron diseases.[1] [2] [3] VLB: conceptualization, data curation, formal analysis, writing – original draft preparation and supervision; HLCM, PHAF, FPS: conceptualization, formal analysis, writing – original draft preparation; IBF: conceptualization, data curation and writing – original draft preparation; PLS: BMLB, MATC, WBVRP: Conceptualization, data curation, formal analysis, writing – review & editing and supervision; PVSS, ASBO: Conceptualization, data curation and writing – review & editing. Received: 15 October 2023 Accepted: 03 December 2023 Article published online: 23 February 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- Open Access
- 27 October 2023
- Published by Springer Nature in Research Square
Chronic intracranial recordings in the basal ganglia reveal patient-specific circadian rhythms in Parkinson's disease
Adaptive deep brain stimulation (aDBS) is a promising therapeutic approach for subjects with Parkinson’s disease (PD) using neural signals as feedback control to adjust the level of therapy. However, the circadian fluctuation of neural signals may alter these control signals and possibly result in suboptimal therapy. We report a large retrospective cohort including 119 subjects with PD (165 hemispheres) with globus pallidus internus (GPi) and subthalamic nucleus (STN) activity recorded chronically in the home environment. Both GPi and STN activity was significantly altered by circadian rhythms. The direction of the circadian rhythm (increase versus decrease at night) depended on the frequency band in both the GPi and STN. The use of long-acting extended released dopaminergic medications significantly impacted the circadian rhythms in the GPi target. These findings demonstrate the variability of chronic circadian rhythms and suggest that aDBS will likely need to account for these patient-specific fluctuations to ensure successful implementation in real-world environments.
- 27 October 2023
- Published by Springer Nature in Research Square
Open AccessChronic intracranial recordings in the basal ganglia reveal patient-specific circadian rhythms in Parkinson's disease
Adaptive deep brain stimulation (aDBS) is a promising therapeutic approach for subjects with Parkinson’s disease (PD) using neural signals as feedback control to adjust the level of therapy. However, the circadian fluctuation of neural signals may alter these control signals and possibly result in suboptimal therapy. We report a large retrospective cohort including 119 subjects with PD (165 hemispheres) with globus pallidus internus (GPi) and subthalamic nucleus (STN) activity recorded chronically in the home environment. Both GPi and STN activity was significantly altered by circadian rhythms. The direction of the circadian rhythm (increase versus decrease at night) depended on the frequency band in both the GPi and STN. The use of long-acting extended released dopaminergic medications significantly impacted the circadian rhythms in the GPi target. These findings demonstrate the variability of chronic circadian rhythms and suggest that aDBS will likely need to account for these patient-specific fluctuations to ensure successful implementation in real-world environments.